S'abonner

Anti-Fc?RIIB mAb suppresses murine IgG-dependent anaphylaxis by Fc domain targeting of Fc?RIII - 05/04/18

Doi : 10.1016/j.jaci.2017.05.027 
Corey D. Clay, MD, PhD a, Richard T. Strait, MD b, d, Ashley Mahler, BS d, Marat V. Khodoun, PhD a, b, Fred D. Finkelman, MD a, c, e,
a Division of Immunology, Allergy and Rheumatology, Department of Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 
b Department of Research, Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio 
c Department of Medicine, Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio 
d Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 
e Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 

Corresponding author: Fred D. Finkelman, MD, Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0563.Division of Immunology, Allergy and RheumatologyUniversity of Cincinnati College of MedicineCincinnatiOH45267-0563

Abstract

Background

The inhibitory receptor FcγRIIB is expressed on human and murine bone marrow–derived cells and limits inflammation by suppressing signaling through stimulatory receptors.

Objective

We sought to evaluate the effects of K9.361, a mouse IgG2a alloantibody to mouse FcγRIIB, on murine anaphylaxis.

Methods

Wild-type and FcγR-deficient mice were used to study anaphylaxis, which was induced by injection of 2.4G2 (rat IgG2b mAb that binds both FcγRIIB and the stimulatory receptor FcγRIII), by actively immunizing IgE-deficient mice and then challenging with the immunizing antigen, and by passive immunization with IgG or IgE anti–2,4,6-trinitrophenyl mAb, followed by injection of 2,4,6-trinitrophenyl–ovalbumin. Pretreatment with K9.361 was assessed for its ability to influence anaphylaxis.

Results

Unexpectedly, K9.361 injection induced mild anaphylaxis, which was both FcγRIIB and FcγRIII dependent and greatly enhanced by β-adrenergic blockade. K9.361 injection also decreased expression of stimulatory Fcγ receptors, especially FcγRIII, and strongly suppressed IgG-mediated anaphylaxis without strongly affecting IgE-mediated anaphylaxis. The F(ab′)2 fragment of K9.361 did not induce anaphylaxis, even after β-adrenergic blockade, and did not deplete FcγRIII or suppress IgG-mediated anaphylaxis but prevented intact K9.361-induced anaphylaxis without diminishing intact K9.36 suppression of IgG-mediated anaphylaxis.

Conclusion

Cross-linking FcγRIIB to stimulatory FcγRs through the Fc domains of an anti-FcγRIIB mAb induces and then suppresses IgG-mediated anaphylaxis without affecting IgE-mediated anaphylaxis. Because IgG- and IgE-mediated anaphylaxis can be mediated by the same cell types, this suggests that desensitization acts at the receptor rather than cellular level. Sequential treatment with the F(ab′)2 fragment of anti-FcγRIIB mAb followed by intact anti-FcγRIIB safely prevents IgG-mediated anaphylaxis.

Le texte complet de cet article est disponible en PDF.

Key words : Fc receptors, anaphylaxis, mouse, signaling, IgG, IgE

Abbreviations used : EW, FcγR, FcRγ, FSC, ITAM, ITIM, MFI, OVA, SSC, TNP, WT


Plan


 Supported by National Institutes of Health (NIH) grant R01 AI113162, a Merit Award to F.D.F. from the US Department of Veterans Affairs, the NIH-supported Immunology/Allergy Fellowship Training Program (T32AI060515-11), and the Department of Internal Medicine, University of Cincinnati Medical Center.
 Disclosure of potential conflict of interest: C. D. Clay receives grant support from the National Institutes of Health (NIH). F. D. Finkelman serves as a consultant for Vedanta Bioscience, is an employee of the University of Cincinnati, receives grant support from the NIH and Food Allergy Research & Education (FARE), and has 3 patents pending with the University of Cincinnati. The rest of the authors declare that they have no relevant conflicts of interest.


© 2017  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 141 - N° 4

P. 1373 - avril 2018 Retour au numéro
Article précédent Article précédent
  • Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2-4-6 study
  • Javier Molina-Infante, Ángel Arias, Javier Alcedo, Ruth Garcia-Romero, Sergio Casabona-Frances, Alicia Prieto-Garcia, Ines Modolell, Pedro L. Gonzalez-Cordero, Isabel Perez-Martinez, Jose Luis Martin-Lorente, Carlos Guarner-Argente, Maria L. Masiques, Victor Vila-Miravet, Roger Garcia-Puig, Edoardo Savarino, Carlos Teruel Sanchez-Vegazo, Cecilio Santander, Alfredo J. Lucendo
| Article suivant Article suivant
  • MicroRNA-150 controls differentiation of intraepithelial lymphocytes through TGF-? receptor II regulation
  • Sang-Hwan Seo, Min Seong Jang, Doo-Jin Kim, Seok-Min Kim, Se-Chan Oh, Cho-Rok Jung, Yunji Park, Sang-Jun Ha, Haiyoung Jung, Young-Jun Park, Suk Ran Yoon, Inpyo Choi, Tae-Don Kim

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.